MYR GMBH

MYR Pharmaceuticals is focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D virus infections. MYR’s lead compound bulevirtide (Myrcludex), a first-in-class entry inhibitor for the treatment of chronic hepatitis B and D infections, progresses into a phase III clinical study for the indication of chronic HDV infection. The drug candidate has received Orphan Drug Designations for the treatment of HDV infection from the European Medicine... s Agency (EMA) and from the U.S. Food & Drug Administration (FDA). In addition, the EMA has granted PRIority MEdicines (PRIME) scheme eligibility. In parallel the FDA has granted Breakthrough Therapy designation. The British Medicines and Healthcare products Regulatory Agency (MHRA) has recently issued the Promising Innovative Medicine (PIM) designation for MYR’s lead compound Bulevirtide. In addition to hepatitis, bulevirtide has a potential for the treatment of a variety of inflammatory and metabolic diseases via additional pharmacological effects of NTCP inhibition. MYR Pharmaceuticals and its collaborators have obtained encouraging preclinical data that support further development of bulevirtide to treat dyslipidemia, nonalcoholic steatohepatitis (NASH), and primary biliary cholangitis (PBC). A Phase 1 clinical trial for dyslipidemia has been initiated. MYR Pharmaceuticals is headquartered in Bad Homburg (Germany). The company started its operations in 2011 and has raised more than EUR 30 million from a number of venture capital investors - including the German High-Tech Gründerfonds - and private investors. The technology was originally developed at the University of Heidelberg (Germany) by Prof. Dr. Stephan Urban and INSERM (France) by Prof. Dr. Phillipe Gripon and represents one the most clinically advanced novel approaches for the treatment of hepatitis B and D.More